Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 20 07 2018
revised: 14 01 2019
accepted: 14 02 2019
pubmed: 27 2 2019
medline: 30 11 2019
entrez: 27 2 2019
Statut: ppublish

Résumé

To examine the relationship between lung radiation dose and survival outcomes in children undergoing total body irradiation (TBI)-based hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia on the Children's Oncology Group trial. TBI (1200 or 1320 cGy given twice daily in 6 or 8 fractions) was used as part of 3 HSCT preparative regimens, allowing institutional flexibility regarding TBI techniques, including lung shielding. Lung doses as reported by each participating institution were calculated for different patient setups, with and without shielding, with a variety of dose calculation techniques. The association between lung dose and transplant-related mortality, relapse-free survival, and overall survival (OS) was examined using the Cox proportional hazards regression model controlling for the following variables: TBI dose rate, TBI fields, patient position during TBI, donor type, and pre-HSCT minimal residual disease level. Of a total of 143 eligible patients, 127 had lung doses available for this analysis. The TBI techniques were heterogeneous. The mean lung dose was reported as 904.5 cGy (standard deviation, ±232.3). Patients treated with lateral fields were more likely to receive lung doses ≥800 cGy (P < .001). The influence of lung dose ≥800 cGy on transplant-related mortality was not significant (hazard ratio [HR], 1.78; P = .21). On univariate analysis, lung dose ≥800 cGy was associated with inferior relapse-free survival (HR, 1.76; P = .04) and OS (HR, 1.85; P = .03). In the multivariate analysis, OS maintained statistical significance (HR, 1.85; P = .04). The variability in TBI techniques resulted in uncertainty with reported lung doses. Lateral fields were associated with higher lung dose, and thus they should be avoided. Patients treated with lung dose <800 cGy in this study had better outcomes. This approach is currently being investigated in the Children's Oncology Group AALL1331 study. Additionally, the Imaging and Radiation Oncology Core Group is evaluating effects of TBI techniques on lung doses using a phantom.

Identifiants

pubmed: 30807822
pii: S0360-3016(19)30266-4
doi: 10.1016/j.ijrobp.2019.02.034
pmc: PMC6548591
mid: NIHMS1525832
pii:
doi:

Substances chimiques

Immunosuppressive Agents 0
Etoposide 6PLQ3CP4P3
Cyclophosphamide 8N3DW7272P
Thiotepa 905Z5W3GKH

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

513-521

Subventions

Organisme : NCI NIH HHS
ID : P01 CA214278
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA029511
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL069254
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC45220
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA098543
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180803
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Pathol Biol (Paris). 1979 Jun;27(6):353-5
pubmed: 388310
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):876-84
pubmed: 16199317
Bone Marrow Transplant. 2001 May;27(9):893-8
pubmed: 11436099
Bone Marrow Transplant. 1993 Sep;12(3):225-31
pubmed: 8241981
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):812-8
pubmed: 20932682
Radiother Oncol. 1999 Sep;52(3):269-76
pubmed: 10580875
Chest. 1985 Feb;87(2):237-46
pubmed: 2981658
Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):463-70
pubmed: 6156148
Radiother Oncol. 1997 Jan;42(1):77-85
pubmed: 9132830
Bone Marrow Transplant. 2001 Sep;28(5):425-34
pubmed: 11593314
Bone Marrow Transplant. 2015 Sep;50(9):1173-9
pubmed: 25961775
Med Dosim. 1998 Winter;23(4):299-301
pubmed: 9863731
Int J Hematol. 2006 Jan;83(1):86-91
pubmed: 16443559
Pathol Biol (Paris). 1979 Jun;27(6):363-4
pubmed: 388313
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1601-6
pubmed: 8503576
Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624
pubmed: 28087456
Int J Radiat Oncol Biol Phys. 1980 Feb;6(2):245-50
pubmed: 7390898
Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1167-73
pubmed: 8083087
Tohoku J Exp Med. 2004 Apr;202(4):255-63
pubmed: 15109123
Int J Radiat Oncol Biol Phys. 1978 Nov-Dec;4(11-12):931-6
pubmed: 721655
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):349-59
pubmed: 26853343
Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):61-6
pubmed: 8823259
J Appl Clin Med Phys. 2015 Mar 08;16(2):5293
pubmed: 26103198
Int J Radiat Oncol Biol Phys. 1976 Mar-Apr;1(5-6):549-52
pubmed: 972116
Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):99-107
pubmed: 6154027
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1297-304
pubmed: 17881143
Bone Marrow Transplant. 1994;14 Suppl 4:S19-28
pubmed: 7728120
Pathol Biol (Paris). 1979 Jun;27(6):357-9
pubmed: 388311
J BUON. 2008 Apr-Jun;13(2):253-62
pubmed: 18555474
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1131-6
pubmed: 9276381
Int J Radiat Oncol Biol Phys. 1981 Oct;7(10):1365-70
pubmed: 7033190
Int J Radiat Oncol Biol Phys. 1983 Jul;9(7):1029-33
pubmed: 6305894
Am J Respir Crit Care Med. 2002 Sep 1;166(5):641-5
pubmed: 12204858
J Clin Oncol. 2016 May 1;34(13):1537-43
pubmed: 26884558
Blood. 1977 Apr;49(4):511-33
pubmed: 14751

Auteurs

Natia Esiashvili (N)

Emory University Winship Cancer Institute, Atlanta, Georgia. Electronic address: nesiash@emory.edu.

Xiaomin Lu (X)

Children's Oncology Group Data Center, Biostatistics, University of Florida, Gainesville, Florida.

Ken Ulin (K)

Imaging and Radiation Oncology Rhode Island QA Center, Lincoln, Rhode Island.

Fran Laurie (F)

Imaging and Radiation Oncology Rhode Island QA Center, Lincoln, Rhode Island.

Sandy Kessel (S)

Imaging and Radiation Oncology Rhode Island QA Center, Lincoln, Rhode Island.

John A Kalapurakal (JA)

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Thomas E Merchant (TE)

St Jude Children's Research Hospital, Memphis, Tennessee.

David S Followill (DS)

Imaging and Radiation Oncology Rhode Island QA Center, Houston, Texas.

Vythialinga Sathiaseelan (V)

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Mary K Schmitter (MK)

Imaging and Radiation Oncology Rhode Island QA Center, Lincoln, Rhode Island.

Meenakshi Devidas (M)

Children's Oncology Group Data Center, Biostatistics, University of Florida, Gainesville, Florida.

Yichen Chen (Y)

Children's Oncology Group Data Center, Biostatistics, University of Florida, Gainesville, Florida.

Donna A Wall (DA)

Manitoba Blood and Marrow Transplant Program, Winnipeg, Manitoba, Canada.

Patrick A Brown (PA)

Johns Hopkins University Kimmel Cancer Center, Baltimore, Maryland.

Stephen P Hunger (SP)

Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, Pennsylvania.

Stephan A Grupp (SA)

Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, Pennsylvania.

Michael A Pulsipher (MA)

Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH